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Abstract 
 
Introduction: current evidence for oncoplastic breast conservation (OBC) is 
based on single institutional series. Therefore, we carried out a population-based 
audit of OBC practice and outcomes in Scotland.  
 
Methods: a predefined database of patients treated with OBC was completed 
retrospectively in all breast units practicing OBC in Scotland.  
 
Results: 589 patients were included from 11 units. Patients were diagnosed 
between September 2005 and March 2017. High volume units performed a mean 
of 19.3 OBCs per year vs. low volume units who did 11.1 (p=0.012). 23 different 
surgical techniques were used. High volume units offered a wider range of 
techniques (8 – 14) than low volume units (3 – 6) (p=0.004). OBC was carried 
out as a joint operation involving a breast and a plastic surgeon in 389 patients. 
Immediate contralateral symmetrisation rate was significantly higher when OBC 
was performed as a joint operation (70.7% vs. not joint operations: 29.8%; 
p<0.001). The incomplete excision rate was 10.4% and was significantly higher 
after surgery for invasive lobular carcinoma (18.9%; p=0.0292), but was 
significantly lower after neoadjuvant chemotherapy (3%; p=0.031). 9.2% of 
patients developed major complications requiring hospital admission. Overall 
the complication rate was significantly lower after neoadjuvant chemotherapy 
(p=0.035). The 5 year local recurrence rate was 2.7%, which was higher after 
OBC for DCIS (8.3%;) than invasive ductal cancer (1.6%; p=0.026). 5-year 
disease-free survival was 91.7%, overall survival was 93.8%, and cancer-specific 
survival was 96.1%.  
   
Conclusion: this study demonstrated that measured outcomes of OBC in a 
population-based multi-centre setting can be comparable to the outcomes of 
large volume single centre series.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Mastectomy, Segmental; Mammaplasty; Breast reconstruction; Breast 
surgery; Breast conservation therapy; Postoperative complications 
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Introduction 
 Oncoplastic breast conserving surgery has become an integral part of 
breast cancer surgical treatment over the last two decades 1. The evidence for 
oncoplastic breast conservation (OBC) is limited and prospective randomized 
controlled trials are unlikely ever to be undertaken given the complex ethical 
implications 2. 
 Current evidence is largely based on single-institution retrospective 
series 3-15. Systematic literature reviews, meta-analyses and reviews further 
strengthen the evidence base but numbers in many series are small 2, 16-24. The 
majority of data reflect the practice of high-volume, mainly tertiary referral 
centres with few data outside of such units. There is only a single study 
underway to delineate OBC practice prospectively in a multi-unit level 25. Due to 
the lack of robust data outside of the previously mentioned larger units, the 
published outcomes of OBC do not mirror the results of the majority of patients 
who are treated outside of these centres. OBC is a rapidly developing field in 
breast cancer surgery, so it is vital to gain “real-life” data.   
 Oncoplastic breast conserving surgery practice has been studied in each 
breast unit from a geographically well-defined area in order to get “real-life” 
experience in OBC practice and outcomes. In Scotland, all patients treated with 
oncoplastic breast conservation were analysed with regards to indications, 
oncoplastic surgical techniques, incomplete excision rate, complication rate, 
(neo)adjuvant treatment and recurrence rate.  
 
 
Methods 
 
 A predefined database was filled in retrospectively from all breast units 
who practise oncoplastic breast conservation in Scotland. The following 
characteristics were collected: age, date of diagnosis and surgery, presentation, 
oncoplastic surgical technique, immediate contralateral symmetrisation, tumour 
type, invasive tumour size, whole tumour size, grade, ER and HER-2 expression, 
lymph node status, multifocality, excision margins, neoadjuvant systemic 
treatment, adjuvant chemo-, radio-, hormonal, and anti-HER-2 treatment, 
postoperative complication, date and site of recurrence, date and cause of death, 
date of last follow-up, presence of plastic surgeon at the operation. Units were 
asked to enter patients treated with OBC consecutively. Patients who needed 
completion mastectomy or who had distant metastasis at presentation were 
excluded. 
 Oncoplastic technique was determined by the ratio of tumour size to 
breast size, tumour location, and patients' anatomy and preferences. This was 
decided subjectively by oncoplastic breast surgeons, or breast and plastic 
surgeons together. Only patients who underwent significant volume excision 
followed by volume displacement accompanied by adequate skin envelope 
reduction, or true volume replacement were included (level II oncoplastic 
techniques as defined by Clough et al.) 26. Patients treated with simple reshaping 
such as dual plane mobilization without skin envelope reduction were not 
included in the study.  
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 Units were classified as high and low volume units based on the number 
of OBC done per year. A high volume unit was defined as one which reported at 
least 100 patients having OBC over two consecutive years.  
 Joint operations were defined as OBC carried out by a breast (general) 
and a plastic surgeon together. When a breast surgeon operated together with 
another breast surgeon, a breast surgical trainee or an oncoplastic fellow, this 
did not count as a joint procedure.  
 Incomplete margins were determined by local guidelines of the time. 
Since 2016, a 1 mm clear margin was considered to be satisfactory for invasive 
and in-situ disease, while 1 or 2 mm clear margin was required previously in 
some of the Units in Scotland 27. Overall survival was defined as the time from 
the date of surgery to the date of death due to any cause, while cancer specific 
survival is defined as death due to breast cancer. Disease-free survival (DFS) was 
defined as the time from the date of surgery to the date of the first relapse or the 
date of death due to any cause. DFS events were defined as any ipsilateral or 
contralateral breast recurrence (invasive or non-invasive), regional or distant 
metastases. Patients who were alive or diseased were censored at the time of last 
follow-up.  
 Complications were classified as major or minor. A major complication 
was considered when readmission or prolonged hospital admission was 
required for subsequent treatments, that were mainly further surgery for 
complications and / or intravenous antibiotic administration. All other 
subsequent treatment not requiring inpatient care was classified as a minor 
complication.  
 Chi-square and Mann-Whitney U tests were used for comparison of 
categorical variables. For comparison between case-load of units or case 
numbers of time periods ANOVA test was used. For correlation between the case 
load of units and the number of oncoplastic techniques offered Spearman's rho 
test was used. A P-value equal to or less than 0.05 was considered statistically 
significant. 
 
 
 
Results 
 
 589 patients were included in the analysis. The median age was 56 years 
[range 21-86]. Almost two-thirds of the patients were from the symptomatic 
service (273 (62.7%); one third from breast screening: 159 (36.5%), and the 
remainder from follow-up or family history clinics between September 2005 and 
March 2017. The number of patients treated with OBC in a unit ranged between 
4 and 145 (Table 1). 11 of 17 units practising oncoplastic breast conservation 
contributed to the study. The 6 remaining units are relatively small units and 
they do not practise OBC. Of these, high volume units performed a mean of 19.3 
cases per year [17,3 – 26,5] vs. low volume units doing 11.1 cases per year [7 .7– 
14.4] (p=0.012) (Table 2). Between 2005 and 2010 the number of patients 
treated with OBC in Scotland increased yearly. In 2005 - 2010 a mean of 20 
patients per year [5-42] were treated with OBC. This trend plateaued after 2011 
when no further increase was observed (2011 – 2016: mean of 76 patients per 
year [51-121] (p=0.002)).  
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 23 different oncoplastic surgical techniques were used (Table 3). The 
number of oncoplastic techniques performed in a unit was associated with case-
load: high volume units used a wider range of surgical techniques (8 – 14 
different oncoplastic techniques per unit) compared to low volume units (3 – 6 
different techniques) (p=0.004) (Table 4). Oncoplastic reduction techniques 
(volume displacement) were used in 515 patients (91.3%), compared to volume 
replacement oncoplastic technique in 49 patients (8.7%) (Table 3). Immediate 
symmetrisation was carried out in 336 patients (57%). The immediate 
symmetrisation rate in patients treated with oncoplastic reduction 
mammoplasty was 61.7% (327 of 530 patients). The joint operation rate was 
66.3%  (389 patients). Immediate contralateral symmetrisation rate was 
significantly higher when the procedure was carried out as a joint operation 
(70.7% vs. not joint operations: 29.8%; p<0.001).  
 The median invasive tumour size was 21 mm [0-120] and the median 
whole tumour size was 26 mm [1-200]. Although there was a trend that the 
median whole tumour size was larger in patients who were operated on in high 
volume units (28 mm [1-180]) when compared to patients treated in low volume 
units (25 mm [7-200]), this difference was not significant (p=0.164).  Details of 
tumour characteristics are summarized in Table 5.  
 The neodjuvant systemic treatment rate was 28.6% (142 of 496 patients 
with invasive carcinoma). Of those, 68 patients received neoadjuvant 
chemotherapy (13.7%) and 74 patients had neoadjuvant hormonal treatment 
(14.9%). 208 patients received adjuvant chemotherapy, 419 patients received 
(neo)adjuvant hormonal treatment including 10 patients with DCIS, and anti-
HER-2 treatment was given to 71 patients. Adjuvant radiotherapy was given to 
all patients when clinically indicated except eight patients with invasive ductal, 
four patients with DCIS, one patient with invasive lobular and one patient with 
Paget’s disease.  
 The incomplete excision rate was 10.4% (60 of 578) and was significantly 
higher in invasive lobular carcinoma (18.86%; 10 of 53) when compared to 
invasive ductal carcinoma (9.2%; 38 of 413; p=0.029). Incomplete excision rate 
after DCIS was similar to invasive ductal carcinoma (8.97%; 7 of 78). After 
neoadjuvant chemotherapy incomplete excision rate was significantly lower 
(2.94%; 2 of 68 vs. no neoadjuvant treatment: 9.89%; 35 of 354; p=0.031) than 
when no neoadjuvant treatment was used. When the whole tumour size was 
larger than the invasive component, incomplete excision rate was higher 
compared to those cases when whole tumour size was the same as the invasive 
tumour size, but this difference was not significant (14.96%; 19 of 127 vs. 
10.33%; 28 of 271; p=0.092). Case load did not influence incomplete excision 
rate (high volume: 9.77%; 39 of 399 vs. low volume: 10.65%; 18 of 169). 
Similarly, incomplete excision rate was almost identical when OBC was 
performed as a joint case with a plastic surgeon (10.05%; 39 of 388 vs. 10.66%; 
21 of 197).  
 145 of 510 patients developed complications, giving an overall 
complication rate of 28.4%. 47 patients had major complications (9.2%) and 98 
patients had minor complications (19.2%) (Table 6). Overall complication rate 
was significantly lower after neoadjuvant chemotherapy (15.9%; 11 of 69) 
compared to patients who did not receive neoadjuvant chemotherapy (27.9%; 
127 of 455 patients) (p=0.035). Case load had no influence on complication rates 
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(high volume units: 24.2%; 98 of 401 vs. low volume units: 24.7%; 42 of 170). 
When complication rate was analysed by date of surgery, it was significantly 
higher in the third of the patients who were operated earlier, between July 2005 
and July 2012 (37.2%; 73 of 196) compared to the third of patients operated on 
between July 2012 and February 2015 (23.9%; 40 of 167; p=0.006) or the third 
of patients operated on most recently, between February 2015 and April 2017 
(21.8%; 32 of 147; p=0.002).  
 Median follow-up time for all patients was 30 months [1-129]. Of those, 
259 patients diagnosed with (non)invasive carcinoma had a median follow-up 
time of 5 years [35-124]. Of these 7 patients (2.7%) developed isolated local 
recurrence. 5-year local recurrence rate after DCIS was higher than after pure 
invasive ductal carcinoma (DCIS: 8.3%; 3 of 36 vs. ductal: 1.6%; 3 of 181; 
p=0.026). 5-year disease-free survival was 91.7%, overall survival was 93.8%, 
and cancer-specific survival was 96.1%. 5-year DFS was somewhat lower in 
patients who had major postoperative complication compared to patients with 
minor or no complication, but this was not significant (86.11%; 5 of 36 vs. 
92.1%; 16 of 204; p=0.236). 
 
 
Discussion 
 
 Evidence for OBC is largely based on single centre retrospective series 16. 
Breast centres that publish their experience on OBC are usually high-volume 
units, tertiary referral centres, which are the most experienced units in complex 
breast surgery 3-6, 10, 15, 28, 29. It is well established that the outcomes of surgical 
breast cancer treatment in centres with significantly higher hospital volume are 
superior 30-32. However, only a minority of patients are treated in such units 
overall. It is conceivable that the outcome results in the published meta-analyses 
on OBC are skewed, as those are predominantly based on data from centres of 
excellence 2, 16-18. As the majority of patients are treated outside of these units, it 
is important to acquire outcome results reflecting the “real-life” scenario. Hence, 
we carried out a population-based audit of practice and outcomes of OBC 
involving all breast units in Scotland.  
 Individual breast units in Scotland were carrying out between 8 – 26 OBC 
operations per year, with an average between 11 cases (low volume units) to 19 
cases (high volume units) yearly. This is comparable to data published by Clough 
et al., who found that 13.9% of breast conserving surgeries were OBC in France, 
based on a representative survey including 33 nationally renowned breast 
surgeons 33. However the numbers of OBC procedures performed yearly were 
much higher in the previously mentioned leading units worldwide in comparison 
to breast units in Scotland. It ranged from 32 to 147 cases per year, and it was 
particularly high in the European Institute of Oncology, MD Anderson Cancer 
Center and the Division of Surgical Oncology, Emory University 4, 10, 15, 28, 29.  
 A variety of oncoplastic techniques were used in the Scottish units for 
OBC. The vast majority of patients were treated with oncoplastic reduction 
techniques (91.3%), while only a small number had volume replacement surgery 
(8.7%). Others published similarly low rates of volume replacement amongst all 
OBC. Rezai et al. applied volume replacement in 5.1% of 1035 patients treated 
with OBC 28. De La Cruz et al. reported on 6011 patients in a meta-analysis and 
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found that 9.5% of patients were treated with volume replacement 16. De Lorenzi 
et al. applied volume replacement in 10.3% of 454 OBC patients 10. Amongst 
oncoplastic reduction techniques Wise pattern reduction was the most 
frequently applied technique (66.5%) followed by round block excision (6.1%) 
in Scotland. This trend was similar to other published series, although the 
dominance of Wise pattern reduction ranged from 35.4% to 87% 5, 16, 34. 
Similarly, immediate symmetrisation rate, which was 61.7% in Scotland, varied 
significantly in the published literature. Rietjens et al. performed contralateral 
symmetrisation in all cases in a series of 148 patients, while Fitoussi et al. 
reported only 46.1% immediate symmetrisation rate in a series of 540 patients 3, 
35.  
 Median whole tumour size of 26 mm and invasive tumour size of 21 mm 
in the Scottish series was comparable to results of others. Clough et al. published 
exactly the same tumour size in a series of 350 OBC patients, while Fitoussi et al. 
published 29.1 mm median tumour size in their series 3, 4. McIntosh et al. 
reported a mean tumour size ranging between 15 and 32.5 mm in a meta-
analysis containing 1702 patients 19. De La Cruz et al. reported 23 mm, while 
Losken et al. reported 27 mm in two meta-analyses, respectively 16, 18. However, 
many of the above studies report on invasive tumour size only 3, 16, 18, 19. 
 Overall incomplete excision rate of 10.4% in the Scottish series was 
similar to the figures published elsewhere 3, 4, 16, 18, 28. However, our study did not 
include patients who required completion mastectomy after failed OBC. Previous 
studies from our unit indicated a completion mastectomy rate between 0 - 13.2% 
of patients treated with OBC indicating a relatively high completion mastectomy 
rate after initially failed OBC 8, 9, 14, 36, 37. Although these figures cannot be 
projected to the practice of the whole country, it is conceivable that true 
incomplete margin rate after OBC is somewhat higher in Scotland. Interestingly, 
many of the large retrospective series do not report on completion mastectomy 
rates either 4, 10, 11, 15. Others report a completion mastectomy rate between 1 – 
9.4% of patients treated with OBC 3, 5, 28, 35, 38. We found a higher incomplete 
excision rate after OBC for invasive lobular carcinoma compared to ductal 
(18.86% vs. 9.2%: p=0.029), which is similar to findings published elsewhere 4.  
 Complications are generally poorly defined in the majority of 
publications, with no definitions or classification provided in the methods 3, 15, 16, 
19, 28, 29. We classified complications as major or minor complications based on 
the necessity of hospital admission. In our series 9.2% of the patients had major 
complication, although there was a significant decrease in complication rates 
noted as units gained experience in OBC techniques. The overall complication 
rate of 28.4% is higher compared to large series of single institutions or 
complication rates reported in meta-analyses 2-4, 10, 15, 16, 28. This can be explained 
by the multi-centre nature of our series with initially less experience in OBC 
techniques. Interestingly, we found a significantly lower overall complication 
rate after neo-adjuvant chemotherapy (15.9%) despite others reporting no 
difference in complication rates after neo-adjuvant chemotherapy followed by 
OBC or mastectomy 4, 39.     
 The 2.7% 5-year local recurrence rate and 91.7% DFS in this study is at 
the lower end of single institutional studies or meta-analyses reporting on 
recurrence rates after OBC 2-4, 10, 15-19, 28. Interestingly, we found a trend towards 
a lower DFS in patients with major complications compared to patients who had 
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no complication (86.1% vs. 92.1%). It has been suggested previously that 
postoperative complications after postmastectomy breast reconstruction worsen 
prognosis although this has not been demonstrated after OBC as yet 40, 41.   
 Our study has a few limitations.  We did not determine whether the 
relatively higher complication rate delayed adjuvant therapy or not, although the 
low recurrence rates suggest that it had no significant effect overall. Similarly, 
complications may have had an impact on cosmetic outcome, which was not 
evaluated either. The time period of patients treated with OBC were not identical 
in the various units in this study, which more or less reflects the different 
learning curve for oncoplastic techniques and practices across the country.    
 In conclusion, we demonstrated that outcomes of OBC in Scotland are 
comparable to outcomes of those in the leading high volume breast centres. 
Although this study demonstrated that measured outcomes of OBC in a 
population-based multi-centre setting are not inferior to large volume single 
centre series, we recommend that prospective multi-centre national audits of 
OBC outcomes should be carried out for quality insurance in OBC practice.  
 
 
Legends: 
 
Table 1. Number of patients treated with oncoplastic breast conservation in each 
unit with time periods over which they were carried out.  
 
Table 2. Case load of oncoplastic breast conservation in high and low volume 
units in Scotland with mean cases per year. 
 
Table 3. Oncoplastic surgical techniques used, with frequencies.  
 
Table 4. Relationship between the number of different oncoplastic techniques 
used in each unit and total OBC case-load.  
 
Table 5.  Tumour characteristics of all patients who underwent OBC surgery on 
Scotland with breakdown of those who had at least 5 years follow-up. 1 with 
(non)invasive breast carcinoma; CPR = complete pathological response, [ ] = 
number of patients received neo-adjuvant systemic treatment, 2 invasive cancers 
only, 3 hormone receptor expression was determined for 30 and 19 patients with 
DCIS, respectively; n/a = not applicable  
 
Table 6. Rates of major and minor complications in 510 patients who underwent 
OBC surgery (79 patients had incomplete data).  
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Units Number of 
patients 
Time period 
Western General 
Hospital Edinburgh 
145 April 2005 – 
August 2015 
Victoria Infirmary 
Glasgow 
144 September 2005 – 
March 2017 
Ninewells Hospital 
Dundee  
111 January 2013 – 
October 2016 
Western Infirmary 
Glasgow 
78 July 2005 – 
October 2016 
University Hospital 
Crosshouse 
36 June 2005 – 
December 2015 
Aberdeen Royal 
Infirmary 
31 January 2014 – 
May 2016 
Forth Valley Royal 
Hospital 
13 September 2014 – 
November 2015 
Stobhill Hospital 
Glasgow 
12 March 2006 – 
March 2014 
Glasgow Royal 
Infirmary 
9 July 2005 – April 
2010 
Wishaw General 
Hospital 
6 August 2015 – 
December 2015 
Royal Alexandra 
Hospital Paisley 
4 August 2015 – 
October 2015 
 
Table 1.  
Number of patients treated with oncoplastic breast conservation during the 
indicated time periods in the various units  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
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Units Number of 
patients 
Time period 
reported 
Mean number of 
OBC cases per year 
HIGH VOLUME UNITS 
Ninewells 
Hospital Dundee 
106 4 years 26.5 cases / year 
Western General 
Hospital 
Edinburgh 
142 8 years 17.7 cases / year 
Victoria Infirmary 
Glasgow 
138 8 years 17.2 cases / year 
TOTAL 386 20 years 19.3 cases / year 
LOW VOLUME UNITS 
Aberdeen Royal 
Infirmary 
29 2 years 1.4.5 cases / year 
Western 
Infirmary Glasgow 
76 6 years 12.7 cases / year 
University 
Hospital 
Crosshouse 
31 4 years 7.7 cases / year 
Forth Valley Royal 
Hospital 
13 1 year and 3 
months 
10.4 cases / year 
Stobhill Hospital 
Glasgow 
12 1 year and 3 
months 
9.6 cases / year 
TOTAL 161 14 years and  
6 months 
11.1 cases / year 
 
Table 2.  
Case-load of oncoplastic breast conservation in high and low volume units in 
Scotland with mean number of cases per year. 
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Oncoplastic technique Number of 
patients 
Percentage 
Wise pattern reduction 375 66.5% 
Round block 34 6.1% 
LICAP / TDAP / LTAP 28 5% 
Regnault B-plasty 25 4.4% 
Grisotti flap 24 4.3% 
Vertical Lejour mammoplasty 23 4.1% 
Matrix rotation / J mammoplasty 15 2.7% 
Thoraco-epigastric flap 14 2.5% 
Lateral / medial mammoplasty 11 2% 
Tennis racquet-type excision 8 1.4% 
Melon slice reduction 5 0.9% 
Crescent flap  3 0.5% 
Batwing mammoplasty 3 0.5% 
VY lateral advancement  2 0.4% 
V - mammoplasty 1 0.2% 
Skin pouch mammoplasty 1 0.2% 
S - mammoplasty 1 0.2% 
Rotational advancement flap 1 0.2% 
Local flap (other) 1 0.2% 
Unknown 25 - 
 
Table 3.  
Oncoplastic surgical techniques used. 
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Units Number of 
oncoplastic 
techniques 
Number 
of 
patients 
HIGH VOLUME UNITS 
Ninewells 
Hospital Dundee 
12 111 
Western General 
Hospital 
Edinburgh 
8 145 
Victoria Infirmary 
Glasgow 
14 144 
LOW VOLUME UNITS 
Aberdeen Royal 
Infirmary 
5 31 
Western 
Infirmary Glasgow 
5 78 
University 
Hospital 
Crosshouse 
6 36 
Forth Valley Royal 
Hospital 
3 13 
Stobhill Hospital 
Glasgow 
3 12 
 
 
Table 4.  
Association between the number of different oncoplastic techniques used in a 
unit and case-loads  
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 All patients  Patients1 with 5-year follow-up 
HISTOLOGICAL TYPE n=      (%) n=         (%) 
Ductal 413   (70.2%) 182       (70.3%) 
Lobular 53      (9%) 25          (9.6%) 
Mixed ductal and lobular 6        (1%) 2             (0.8%) 
Mixed ductal and papillary 1        (0.2%) - 
Tubular 7        (1.2%) 4             (1.5%) 
Mucinous 6        (1%) 4             (1.5%) 
Metaplastic 2        (0.3%) 1             (0.4%) 
Not determined (CPR) 5        (0.8%) 1             (0.4%) 
DCIS 78     (13.2%) 36           (13.9%) 
Paget’s disease 2       (0.3%) 2             (0.8%)  
Papillary carcinoma 1        (0.2%) 1             (0.4%) 
LCIS 3       (0.5%) 1             (0.4%) 
Hamartoma 1       (0.2%) n/a 
Phylloides 8       (1.3%) n/a 
Diabetic mastopathy 1       (0.2%) n/a  
Basal cell carcinoma 1       (0.2%) n/a 
Osteosarcoma 1        (0.2%) n/a 
TOTAL 589   (100%) 259        (100%) 
PATHOLOGICAL T STAGE  
Tis 83    (14.4%) 39          (15%) 
-            [ypT0] 13    (2.2%)        [13] 5            (1.9%)         [5] 
T1a  [ypT1a] 18    (3.2%)        [6] 17          (6.6%)         [4] 
T1b [ypT1b] 47    (8.1%)        [10] 28          (10.9%)       [4] 
T1c [ypT1c] 142  (24.6%)     [30] 33          (12.7%)      [11] 
T2 [ypT2] 225  (39%)         [66] 110        (42.5%)      [33] 
T3 [ypT3] 27     (4.7%)       [10] 14          (5.4%)         [10] 
Incomplete data 22     (3.8%)       [17] 13          (5%)             [5] 
TOTAL 577   (100%)     [152] 259        (100%)       [72] 
TUMOUR GRADE2  
Grade 1 50    (10.1%) 26           (11.9%) 
Grade 2 243  (49.2%) 105         (48.2%) 
Grade 3 197  (39.9%) 83           (38.1%) 
Incomplete/ not determined 4       (0.8%) 4              (1.8%) 
TOTAL 494   (100%) 218         (100%) 
HORMONE EXPRESSION3  
ER positive 437  (83.4%) 200         (84.4%) 
ER negative 83     (15.8%) 37           (15.6%) 
Incomplete data 4        (0.8%) - 
TOTAL 524   (100%) 237         (100%) 
HER-2 EXPRESSION2  
HER-2 positive 85     (17.2%) 32           (14.7%) 
HER-2 negative 401   (81.2%) 181        (83%) 
Incomplete/ not determined 8        (1.6%) 5             (2.3%) 
TOTAL 494    (100%) 218        (100%) 
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NODAL METASTASIS2  
Node positive 136    (27.5%) 58           (26.6%) 
Node negative 353    (71.4%) 157         (72%) 
Incomplete 5          (1%) 3              (1.4%) 
TOTAL 494    (100%) 218         (100%) 
FOCALITY  
Multifocal  117    (20.3%) 46           (17.8%) 
Unifocal 440    (76.2%) 208         (80.3%) 
Incomplete / not determined 20       (3.5%) 5              (1.9%) 
TOTAL 577     (100%) 259         (100%) 
 
Table 5.  Tumour characteristics 
1 with (non)invasive breast carcinoma; CPR = complete pathological response, [ ] 
= number of patients received neo-adjuvant systemic treatment, 2 invasive 
cancers only, 3 hormone receptor expression was determined for 30 and 19 
patients with DCIS, respectively; n/a = not applicable  
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 Number of 
patients 
Percentage of 
patients 
All complications  145 28.4% 
MAJOR COMPLICATIONS 
Infection 16 3.1% 
Haematoma 10 2% 
Delayed wound healing 7 1.3% 
Skin necrosis 5 1% 
Fat necrosis 5 1% 
Nipple necrosis 2 0.4% 
Flap insertion delayed 1 0.2% 
Pulmonary embolism  1 0.2% 
TOTAL 47 9.2% 
MINOR COMPLICATIONS 
Infection 27 5.3% 
Delayed wound healing 21 4.1% 
Haematoma 18 3.5% 
Skin necrosis 16 3.2% 
Fat necrosis 11 2.1% 
Nipple necrosis 5 1% 
TOTAL 98 19.2% 
 
 
Table 6. Major and minor complications in 510 patients. 79 patients had 
incomplete data.  
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